YZi Labs, backed by CZ Zhao, challenges CEA Industries over poison pill and bylaw changes, accusing them of being stockholder-unfriendly and aimed at entrenching the current board. YZi is reviewing CEA’s adoption of measures that restrict shareholders’ rights beyond Nevada law, potentially exposing the board to liability for failing fiduciary duties.

CEA responds, denying claims of considering alternative tokens for its digital asset treasury strategy and launching competitive ventures. YZi points to public comments by CEA CEO about other crypto assets, raising concerns about alignment with BNB strategy. YZi also questions promotion of other DAT projects by CEA executives.

CEA defends its actions, stating commitment to BNB DAT strategy, adoption of stockholder rights plan, and bylaw amendments to protect stockholders’ interests. YZi criticizes CEA for delaying the 2025 annual meeting and urges transparent scheduling to allow stockholders to vote on the board’s composition. CEA has not directly responded to YZi’s claims.

YZi spokesperson emphasizes protecting BNC shareholder rights and promoting BNB ecosystem integrity in compliance with SEC requirements. YZi appreciates attention from the community and media, including Cointelegraph. Cointelegraph reached out to CEA Industries for comment, but no response was received at the time of publication.

Read more at Cointelegraph: CZ-Backed YZi Labs Clashes with CEA Industries Over Poison Pill